clinical trial · NCT04797650
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)
Alopecia AreataCTP-543 matching placeboCTP-543
brief summary
This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.
started
Jun 10, 2021
primary completion
Jun 8, 2022
completion
Jun 29, 2022
last updated
Jul 3, 2023
official title
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol